Document:

bpmc_Ex10.2

		

			Exhibit 10.2

		

		

			 

		

		
			[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
		

		
			SIXTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT
		

		
			This Sixth Amendment (this “Sixth Amendment”), effective November 1,  2019 (“Sixth Amendment Effective Date”), is by and between F. Hoffmann-La Roche Ltd, with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland and Hoffmann-La Roche Inc., with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (together referred to as “Roche”), and Blueprint Medicines Corporation,  with a principal place of business at 45 Sidney Street, Cambridge, Massachusetts 02139 U.S.A. (“BPM”). Capitalized terms used and not otherwise defined in this Sixth Amendment shall have the meanings set forth in the Agreement (as defined below).
		

		
			WHEREAS, BPM and Roche entered into a Collaboration and License Agreement,  dated March 14, 2016, as amended by an amendment, effective April 15, 2016, a second amendment, effective April 27, 2016, a third amendment, effective August 4, 2016, a fourth amendment, effective February 25, 2019, and a fifth amendment, effective June 28, 2019 (collectively, the “Agreement”); and
		

		
			WHEREAS, the Parties wish to enable the Joint Research Committee to approve alternative funding arrangements for preclinical development activities conducted under Research Plans as set forth herein;
		

		
			WHEREAS, the Parties wish to be able to conduct preclinical development activities for Collaboration Targets with Roche Clinical Compounds and Roche Marketed Products; 
		

		
			WHEREAS, the Parties wish to terminate [***] as a Collaboration Target under the Agreement;
		

		
			NOW THEREFORE, Roche and BPM hereby agree as follows:
		

			
	
			
				 1.
			Section 1.108 of the Agreement is hereby amended by adding the following sentence to the end of such section:

		
			 
		

		
			“In the event that the JRC approves an Alternative Funding Arrangement for a Collaboration Target, then the Research Plan for such Collaboration Target shall also specify (i)  the budget for the applicable preclinical development activities and (ii) the percentage of the corresponding costs and expenses that each Party (if applicable) will be responsible for funding (e.g., fifty percent-fifty percent cost sharing).”
		

			
	
			
				 2.
			The definition of “Roche Clinical Compounds” in Section 1.110 of the Agreement shall be amended by deleting it in its entirety and replacing it with the following Section 1.110:

		
			 
		

		
			“1.110 Roche Clinical Compounds
		

		
			The term “Roche Clinical Compounds” shall mean clinical-stage compounds controlled by Roche or its Affiliates (but not Products or Licensed Products) and provided for  (i) combination preclinical development activities with Library Compounds, Collaboration Compounds, Other Compounds or Products during Lead Nomination or Lead Optimization, or (ii) combination Clinical Studies with Products or Licensed Products.”
		

		
			 
		

		
			

		 

		

			
	
			
				 3.
			The definition of “Roche Marketed Products” in Section 1.113 of the Agreement shall be amended by deleting it in its entirety and replacing it with the following Section 1.113:

		
			 
		

		
			“1.113 Roche Marketed Products
		

		
			The term “Roche Marketed Products” shall mean marketed products controlled by Roche or its Affiliates (but not Products or Licensed Products) and provided for  (i) combination preclinical development activities with Library Compounds, Collaboration Compounds, Other Compounds or Products during Lead Nomination or Lead Optimization, or (ii) combination Clinical Studies with Products or Licensed Products.”
		

			
	
			
				 4.
			Section 4.1.3 is hereby amended by adding the following paragraph immediately after the first paragraph of Section 4.1.3:

		
			 
		

		
			 “If any Research Plan (or any amendment thereto)  contemplates the conduct of any preclinical development activities [***] by one or more Third Party(ies) on behalf of BPM, such Research Plan (or an amendment thereto) shall also specify (a) the budget for the applicable preclinical development activities and the percentage of the corresponding costs and expenses that each Party (if applicable) will be responsible for funding (e.g., cost sharing fifty percent (50%) by BPM and fifty percent (50%) by Roche), (b) the specific compounds to be used in such activities (including any Roche Clinical Compounds or Roche Marketed Products), (c) the specific Third Party(ies)  that BPM intends to use to conduct such preclinical development activities, and each such Third Party shall be an approved CRO under the Agreement or specified for such activities in the Research Plan,  and (d) any costs previously incurred by BPM related to such activities that are to be retroactively shared by the Parties (and the applicable percentage of such costs that each Party (if applicable) will be responsible for funding).  Any such Research Plan that contemplates the Parties sharing the costs and expenses of any such preclinical development activities performed by one or more Third Party(ies) on behalf of BPM is referred to herein as an “Alternative Funding Arrangement”.”
		

			
	
			
				 5.
			Clause (a) of Section 8.4 of the Agreement is hereby deleted in its entirety and replaced by the following new clause (a):

		
			 
		

		
			“(a) approve each Research Plan and any revisions thereto, including any Alternative Funding Arrangement and Alternative Funding Costs for such Research Plan;”
		

			
	
			
				 6.
			Notwithstanding anything to the contrary in Section 8.8 of the Agreement, all Alternative Funding Arrangements and Alternative Funding Arrangement Costs must be approved by consensus of both Parties’ JRC Members (i.e., neither BPM nor Roche has final decision).

		
			 
		

			
	
			
				 7.
			Section 12.3 of the Agreement is hereby deleted in its entirety and replaced by the following new Section 12.3:

		
			 
		

		
			“12.3 Costs for Work Conducted under Research Plans
		

		
			Except for Alternative Funding Arrangements approved by consensus of the JRC (i.e. neither BPM nor Roche have final decision) pursuant to the JRC’s authority under Section 8.4(c) hereof or as otherwise provided in this Agreement, each Party shall be responsible for its own costs incurred in the conduct of its activities under each Research Plan.
		

		
			Commencing the first Calendar Quarter immediately following BPM incurring costs under an Alternative Funding Arrangement within a  Research Plan (“Alternative Funding Arrangement Costs”) and continuing thereafter so long as BPM incurs costs under such 

		 

		

			2

		

		

			 

		

Alternative Funding Arrangement under this Agreement,  within forty-five (45) days following the end of such Calendar Quarter, BPM shall submit to Roche a report setting forth the Alternative Funding Arrangement Costs incurred by BPM in such Calendar Quarter; provided that if there are any Alternative Funding Arrangement Costs incurred in such Calendar Quarter that BPM is unable to timely include in such financial report, then such amount shall be included and reconciled in the financial report in a future Calendar Quarter. Each such report shall specify in reasonable detail the Alternative Funding Arrangement Costs incurred and shall include reasonably detailed supporting information. Within [***] after receipt of each such report, the Finance Officers (as defined in Section 12.5 below) shall confer and agree in writing on whether a reconciliation payment is due from Roche to BPM, and if so, the amount of such reconciliation payment, so that the Parties share Alternative Funding Arrangement Costs in accordance with the allocation specified in the applicable Research Plan for such Alternative Funding Arrangement.  Roche shall make such payment to BPM within [***] after the end of each Calendar Quarter; provided, however, that in the event of any disagreement with respect to the calculation of such reconciliation payment, any undisputed portion of such reconciliation payment shall be paid in accordance with the foregoing timetable and the remaining, disputed portion shall be paid within [***] after the date on which the Parties, using good faith efforts, resolve the dispute. Notwithstanding anything to the contrary in this Section 12.3, in the event that the JRC approves an Alternative Funding Arrangement for which the approved budget includes costs and expenses previously incurred by BPM that are to be shared retroactively by the Parties (as specified in the applicable Research Plan), then Roche’s portion of such previously incurred costs and expenses shall be included in the first Calendar Quarter report submitted by BPM related to such Alternative Funding Arrangement (or if BPM is unable to timely include such costs and expenses in such financial report, then such amount shall be included and reconciled in the financial report in a future Calendar Quarter).”
		

			
	
			
				 8.
			Section 16.1 of the Agreement is hereby amended by adding the following sentence to the end of such section. 

		
			 
		

		
			“Any and all Collaboration Compounds and all Other Compounds (including Combination Products) for a given Collaboration Target or other Targets, including their methods of manufacture (other than Roche Process IP) and use, and all Patent Rights and Know-How relating thereto (including Collaboration Compound IP) that are created or conceived in connection with a Research Plan shall be solely owned by BPM as Collaboration Compound IP or Other Compound IP, as applicable, except that all Patent Rights and Know-How that solely relate to Roche Clinical Compounds or Roche Marketed Products, including their methods of manufacture (other than Roche Process IP) and use, shall be solely owned by Roche.
		

			
	
			
				 9.
			[***] is classified as a “Terminated Target” under the Agreement in all countries in the Territory in accordance with Section 21.2.4.   Notwithstanding the written notice period set forth in such Section 21.2.4, the effective date of termination of such Terminated Target will be the Sixth Amendment Effective Date.  Further,  the Parties hereby acknowledge and agree that this Sixth Amendment will be deemed to constitute a “Continuation Election Notice” in accordance with Section 21.3.1, and Roche will comply with its obligations under 21.3.1 and 21.3.4; provided that no payment will be due or payable to Roche under Section 21.3.1(f) or 21.3.4.4.  As of the Sixth Amendment Effective Date, (a) the rights and licenses granted by BPM to Roche under the Agreement related to the aforementioned Terminated Target terminate in their entirety in all countries in the Territory, (b) except as set forth herein, the rights and obligations of the Parties under the Agreement terminate with respect to such Terminated Target, (c) Roche’s obligations under Section 20.1 survive with respect to such Terminated Target, and (d) BPM solely owns all Collaboration Compounds and Other Compounds for such Terminated Target, including their methods of manufacture and use, and all Patent Rights and Know-How relating thereto.  Further, for the avoidance of doubt, it is understood 

		 

		

			3

		

		

			 

		

	and agreed that BPM has the right to (i)  research, develop, manufacture, commercialize and otherwise exploit compounds and products related to such Terminated Target outside of the Agreement without any financial obligations to Roche, (ii) publish data and other Know-How related to the Terminated Target (including without limitation the name of the target and Collaboration Compounds and Other Compounds for such Terminated Target) generated by or on behalf of the Parties under the Agreement prior to the Sixth Amendment Effective Date or thereafter without obtaining prior review or approval from Roche and (iii) disclose, in its sole discretion, in a manner consistent with BPM’s then-current disclosure or publication practices or policies that such data or Know-How was generated under the Agreement and/or the names and affiliations of the individuals involved in the generation of such data or Know-How,  if and as applicable.

		
			 
		

		
			This Sixth Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or other electronic signature) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
		

		
			This Sixth Amendment shall be effective as of the Sixth Amendment Effective Date.  On and after the Sixth Amendment Effective Date, each reference in the Agreement to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import, and each similar reference in the other documents entered into in connection with the Agreement, shall mean and be a reference to the Agreement, as amended by this Sixth Amendment.  Except as specifically amended above, the Agreement shall remain in full force and effect in accordance with its terms and is hereby ratified and confirmed.
		

		
			This Sixth Amendment shall be governed by and construed in accordance with the laws of the State of New York, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention).
		

		
			 
		

		
			[Signature page follows.]
		

		
			
		

		
			

		 

		

			4

		

		

			 

		

		

		
			IN WITNESS WHEREOF, the Parties have caused this Sixth Amendment to be executed by their respective duly authorized representatives as of the Sixth Amendment Effective Date.
		

		
			 
		

			
					
						 

					
						

					
						

					
						

					
						 

				
	
					
						Blueprint Medicines Corporation

					
						 

					
						/s/ Jeffrey W. Albers

					
						Name:Jeffrey W. Albers

					
						Title:President and Chief Executive Officer

				

		
			 
		

			
					
						 

					
						 

					
						

					
						

					
						 

					
					
						 

					
						

					
						

					
						

					
						 

				
	
					
						F. Hoffmann-La Roche Ltd

					
						 

					
						/s/ Tim Steven 

					
						Name:Tim Steven

					
						Title: Global Alliance and Asset Management Director

					
					
						 

					
						 

					
						/s/ Stefan Arnold

					
						Name:Stefan Arnold

					
						Title: Head Legal Pharma

				

		
			 
		

			
					
						 

					
						

					
						

					
						

					
						 

				
	
					
						Hoffmann-La Roche Inc.

					
						 

					
						/s/ John P. Praise

					
						Name:John P. Praise

					
						Title:Authorized Signatory

				

		
			 
		

		 

		

			5Exhibit

Exhibit 10.3

RESTRICTED STOCK UNIT AGREEMENT
This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of [•] (the “Award Date”), by and between Reliant Bancorp, Inc., a Tennessee corporation (the “Company”), and [•] (the “Grantee”).
WHEREAS, the Company has adopted the Commerce Union Bancshares, Inc. 2015 Equity Incentive Plan (as amended, the “Plan”), pursuant to which the Committee may grant to Participants Awards of Company common stock, par value $1.00 per share (“Common Stock”), or Awards denominated or payable by reference to, or otherwise based on or related to, Common Stock; and
WHEREAS, in furtherance of and consistent with the purposes of the Plan, and in consideration of the Grantee’s service on the boards of directors of the Company and Reliant Bank, the Company’s wholly owned bank subsidiary (the “Bank”), the Committee has approved the award of Restricted Stock Units (as defined below) provided for herein.
NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:
Section 1.Award of Restricted Stock Units.  

(a)Pursuant to Section 9 of the Plan, the Company hereby awards to the Grantee on the Award Date an Award consisting of, in the aggregate, [•] restricted stock units (the “Restricted Stock Units”). Each Restricted Stock Unit represents the right to receive one share of Common Stock, subject to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms that are used but not defined in this Agreement have the meanings ascribed to them in the Plan.

(b)The Restricted Stock Units shall be credited to a separate account maintained for the Grantee on the books and records of the Company (the “Account”). All amounts credited to the Account shall continue for all purposes to be part of the general assets of the Company.

Section 2.Consideration.  The award of the Restricted Stock Units is made in consideration of the services to be rendered by the Grantee to the Company and the Bank. 

Section 3.Vesting.  

(a)Except as otherwise provided herein, provided that the Grantee has not experienced a Termination of Service prior to the [•] anniversary of the Award Date, all of the Restricted Stock Units will vest on the date that is the [•] anniversary of the Award Date.

(b)Except as otherwise provided in Section 3(c), in the event the Grantee experiences a Termination of Service prior to the time all of the Restricted Stock Units have vested, all of the unvested Restricted Stock Units shall be automatically forfeited by the Grantee upon such Termination of Service and neither the Company nor any Affiliate shall have any further obligations to the Grantee under this Agreement with respect thereto.
(c)In the event the Grantee experiences a Termination of Service prior to the time all of the Restricted Stock Units have vested as a result of the Grantee’s death or Disability, all unvested Restricted Stock Units shall vest as of the date of such Termination of Service.

(d)In the event of a Change in Control, the Committee shall take such action(s) with respect to this Award of Restricted Stock Units as are permitted by Section 12 of the Plan. 

(e)With respect to any Restricted Stock Units, the period of time beginning on the Award Date and ending on the date such Restricted Stock Units vest in accordance with this Section 3 is referred to herein as the “Restricted Period”. Restricted Stock Units that have vested in accordance with this Section 3 are referred to herein as “Vested Units.” 

Section 4.Restrictions.  Subject to any exceptions set forth in this Agreement, during the Restricted Period and until such time as the Restricted Stock Units are settled in accordance with Section 6, neither the Restricted Stock Units nor any rights relating thereto may be assigned, alienated, pledged, attached, sold, or otherwise transferred or encumbered by the Grantee, and any attempt to assign, alienate, pledge, attach, sell, or otherwise transfer or encumber the Restricted Stock Units or any rights relating thereto shall be wholly ineffective and, if any such attempt is made, the Restricted Stock Units will be forfeited by the Grantee and all of the Grantee’s rights to such Restricted Stock Units shall immediately terminate without any payment or consideration by the Company.

Section 5.Rights as Shareholder; Dividend Equivalents.

(a)The Grantee shall not have any rights of a shareholder with respect to the shares of Common Stock underlying the Restricted Stock Units unless and until the Restricted Stock Units vest and are settled by the issuance of such shares of Common Stock.

(b)Upon and following the settlement of the Restricted Stock Units, the Grantee shall be the record owner of the shares of Common Stock underlying the Restricted Stock Units unless and until such shares are sold or otherwise transferred or disposed of and, as record owner of such shares, shall be entitled to all rights of a shareholder of the Company (including voting rights). 

(c)If, prior to the settlement of the Restricted Stock Units, the Company declares a cash or stock dividend on the shares of Common Stock, then, on the payment date of the dividend, the Grantee’s Account shall be credited with dividend equivalents in an amount equal to the cash or stock dividend that would have been paid to the Grantee if one share of Common Stock had been issued on the Award Date for each Restricted Stock Unit granted to the Grantee as set forth in this Agreement (the “Dividend Equivalents”), with the amount to be credited in respect of any stock dividend to be computed using the Fair Market Value of the Common Stock on the payment date of the dividend.

(d)Any Dividend Equivalents shall be withheld by the Company for the Grantee’s Account and no interest shall accrue or be paid thereon. Dividend Equivalents shall be subject to the same vesting and forfeiture restrictions as the Restricted Stock Units to which they are attributable and shall be paid on the same date that the Restricted Stock Units to which they are attributable are settled in accordance with Section 6. Dividend Equivalents credited to a Grantee’s Account shall be distributed in cash.

Section 6.Settlement of Restricted Stock Units.

(a)Subject to Section 8, promptly following the date on which any Restricted Stock Units vest, and in any event no later than March 15 of the calendar year following the calendar year in which such Restricted Stock Units vest, the Company shall (i) issue and deliver to the Grantee the number of shares of Common Stock equal to the number of Vested Units, and cash in an amount equal to any Dividend Equivalents credited with respect to such Vested Units, and (ii) enter the Grantee’s name on the books of the Company as the shareholder of record with respect to the shares of Common Stock delivered to the Grantee. 

(b)Notwithstanding Section 6(a), in accordance with Section 3.1 of the Plan, the Committee may, but is not required to, prescribe rules pursuant to which the Grantee may elect to defer settlement of the Restricted Stock Units. Any deferral election must be made in compliance with such rules and procedures as the Committee deems advisable. 

Section 7.No Right to Continued Service.  This Agreement does not confer upon the Grantee any right to be retained or continue as a director of the Company or the Bank, or any subsidiary of affiliate thereof, or in any other capacity. Further, nothing in this Agreement shall be construed to limit the discretion of the Company or the Bank, or any subsidiary of affiliate thereof, to terminate the Grantee’s service at any time, with or without Cause.

Section 8.Tax Withholding and Liability.

(a)The Company or any Subsidiary or Affiliate shall have the authority and the right to deduct or withhold, or to require the Grantee to pay to the Company or such Subsidiary or Affiliate, an amount sufficient to satisfy any federal, state, local, and foreign tax withholding obligations arising in respect of or in connection with the Restricted Stock Units. Unless otherwise determined by the Committee, such tax withholding obligations shall be satisfied by the Company withholding shares of Common Stock from the shares of Common Stock otherwise deliverable to the Grantee as a result of the vesting of the Restricted Stock Units, provided that there shall not be withheld any shares of Common Stock with a Fair Market Value in excess of the maximum amount of tax required by law to be withheld. 

(b)Notwithstanding any action the Company or any Subsidiary or Affiliate takes with respect to any or all income tax, social security tax, Medicare tax, payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Grantee’s responsibility and the Company (i) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, award, vesting, or settlement of the Restricted Stock Units or the subsequent sale of any shares of Common Stock and (ii) does not commit to structure the Restricted Stock Units to reduce or eliminate the Grantee’s liability for Tax-Related Items.

Section 9.Compliance with Law.  Any issuance or transfer of shares of Common Stock underlying the Restricted Stock Units shall be subject to compliance by the Company and the Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which shares of Company Common Stock may be listed. No shares of Common Stock shall be issued or transferred unless and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel.

Section 10.Notices.  Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Chief Financial Officer of the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the Grantee’s address as shown in the records of the Company. Either party may from time to time designate a different address for notices by notice given in accordance with this Section 10. Any notice provided under this Agreement must be delivered personally to the party to be notified or sent by first class mail, postage prepaid, return receipt requested.   

Section 11.Governing Law.  This Agreement will be construed and interpreted in accordance with the laws of the State of Tennessee without regard to conflict of law principles.

Section 12.Interpretation.  Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Committee (excluding the Grantee if the Grantee then serves on the Committee) for review. The resolution of such dispute by the Committee shall be final and binding on the Grantee and the Company.

Section 13.Restricted Stock Units Subject to Plan.  This Agreement is subject to the Plan. The terms and provisions of the Plan are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained in this Agreement and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

Section 14.Successors and Assigns.  The Company may assign any of its rights and/or delegate any of its obligations under this Agreement without the consent of or notice to the Grantee. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. This Agreement and the Restricted Stock Units, and the Grantee’s rights hereunder and thereto, may be transferred by the Grantee only at death by will or the laws of descent and distribution. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Grantee and the Grantee’s executors and administrators and the person(s) to whom the Restricted Stock Units may be transferred by will or the laws of descent and distribution.

Section 15.Discretionary Nature of Plan.  The Plan and Awards thereunder are discretionary in nature. The award of Restricted Stock Units provided for by this Agreement does not create any contractual right or other right to receive any restricted stock units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Committee.

Section 16.Amendment.  Subject to any limitations set forth in the Plan, the Committee shall have the right to amend the terms of or alter, suspend, discontinue, cancel, or terminate the Restricted Stock Units, prospectively or retroactively; provided that no such amendment, alteration, suspension, discontinuance, cancellation, or termination that would adversely affect the Grantee’s rights under this Agreement shall be effective without the Grantee’s consent. 

Section 17.Section 409A.  This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest, or other expenses that may be incurred by the Grantee on account of non-compliance with Section 409A of the Code. 

Section 18.Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document will have the same effect as physical delivery of the paper document bearing an original signature.

Section 19.Acceptance.  The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms and provisions thereof, and accepts the Restricted Stock Units subject to all of the terms and conditions of the Plan and this Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the vesting or settlement of the Restricted Stock Units or disposition of the underlying shares of Common Stock and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement, or disposition. 

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

RELIANT BANCORP, INC. 

	
					
	By:
	 
	 
	 
	 

	 
	[•]
	 
	[•]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]